comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 02:03:39 - browse：4

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Surgery pushed Ben Carson to fame

WSS

The Biogen Aduhelm mess could happen again

Heat waves linked to early deliveries, preterm births in new study

Unique patient identifier: Experts argue the benefits, pitfalls

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Akili, maker of video game for ADHD, to be acquired for 34 million

AstraZeneca stays mum on Medicare drug pricing negotiations

focus

comprehensive

hotspot

What does generative AI mean for health care? We asked experts

AstraZeneca stays mum on Medicare drug pricing negotiations

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A protest over insulin prices is seen as a fight for life

How to save PrEP access — and even expand it

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Drug repurposing or repositioning? The language matters

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Tori Bowie and the unacceptable rates of Black maternal death

Cano Health’s bankruptcy is a warning for Medicare Advantage

entertainment

Why Novartis is going to walk from its acquisition of MorphoSys

Scientists successfully use ultrasound imaging to map brain activity

David Sabatini, ex

Problems with a popular proposal to regulate AI in health care

Stigma and the return of syphilis

Antibiotic resistance nearly killed me, so I'm raising awareness of it

leisure time

hotspot

focus

Wikipedia